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Limited effect of highly active antiretroviral
therapy among HIV-positive injecting drug
users on the population level
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J. ROY ROBERTSON, ILDEFONSO HERNÁNDEZ AGUADO, JIM MCMENAMIN, ROBERT ZANGERLE, 
ARNAUD FONTANET, ROEL A. COUTINHO, MARIA PRINS *
There is evidence that HIV-positive injecting drug users benefit less than other risk groups from highly active
antiretroviral therapy that has been available since 1996. In this multicentre European study the impact of the
availability of highly active antiretroviral therapy on the progression rates to AIDS and death among injecting drug
users with a documented date of HIV seroconversion is studied. After highly active antiretroviral therapy became
available the risk of AIDS and death for injecting drug users decreased by 28% and 36%, which is less than has
been reported for other risk groups.
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It is not yet clear whether HIV-positive injecting drug users
(IDU) benefit as much as other risk groups from the
general availability since 1996 of HAART (highly active
antiretroviral therapy). Studies on the population level
that include, among others, the IDU risk group, do show
a reduced risk of AIDS and death in 1997 and 19981–4
and these improvements have been shown to be associ-
ated with therapy usage.5 However, most of these studies
concern seroprevalent cohorts in which adjusting fully for
duration of HIV infection is not possible, which leads to
survival estimates in the HAART era that are too
optimistic.6 Only two studies of seroconverters (thus with
known duration of infection) have been published so far,
showing a decreased risk of death of 50% (Italy) and 64%
(Europe) for several risk groups combined in the
1997/1998 time period.5,7 However, IDU who are eligible
for HAART have a lower probability of initiating the
potent drug combinations and also start HAART later
following HIV infection than other risk groups.8–11 So far
risk reduction estimates of AIDS and death in time of
HAART specifically for IDU have not been published.
Therefore, on the population level, we studied the impact
of the general availability of HAART on the progression
rates to AIDS and to death among IDU with documented
date of HIV seroconversion.
METHODS
The study population comprised 751 IDU with a known
date of a seronegative and seropositive HIV test from
seven cohorts in six European countries: the Valencian
HIV Seroconversion Study (n=279), the Edinburgh Drug
Addiction Study and the Edinburgh City Hospital
Cohort Study (combined n=172), the Amsterdam
Cohort Study (n=118), the Geneva HIV Cohort Study
(n=65), the French SEROCO Study (n=40), the Scottish
National Collaborative HIV Testing Study from Glasgow
(n=52) and the Innsbruck AIDS Study (n=25). The
individual cohorts started between 1982 and 1988 and the
design and methodology of each cohort have been
described elsewhere.12 Information on AIDS and cause
of death was obtained from review of medical records and
by matching against local and national registries.
Calendar period of follow-up was evaluated as a time-
dependent covariate in a Cox proportional hazards
model. Three calendar periods were defined when
analysing progression to AIDS: i) time before the
implementation of the expanded European AIDS case
definition, ii) time of the implementation of the
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expanded definition but before general availability of
HAART and iii) time since general availability of
HAART. The reason for distinguishing between time
before and after the 1993 extended AIDS case definition
is that this revision has been shown to increase the
number of AIDS cases especially in IDU13,14 because in
Europe cervix carcinoma, recurrent pneumonia and
pulmonary tuberculosis were added,15 of which the latter
two are common among IDU.16–18 Hence, disregarding
the increase in AIDS hazard in the second period which
may be due to the change in AIDS case definition might
underestimate the effect of HAART on progression to
AIDS in IDU. For progression to death from natural
causes (thus excluding death from suicide, overdose and
unintentional injuries) the first two calendar periods were
combined, as a change in AIDS definition would not
affect survival. In contrast to other studies, and to avoid
misclassification, country-specific cut-off dates were used
for each time period: the 1993 AIDS case definition was
introduced between 1–1–1993 or 1–1–1994 in the
different countries and starting dates for general avail-
ability of HAART varied between March 1996 and
September 1996. Follow-up was calculated from the
estimated time of seroconversion through the endpoint
(AIDS or natural death), lost to follow up or censor date
(maximally 1–1–1998). For AIDS analyses persons who
died pre-AIDS were censored at death and for survival
analyses persons who died of a non-natural cause were
censored at death. In multivariate analyses the effect of
calendar period was also corrected for a combination
variable of geographic region and setting of follow up, as
a clinical setting has been shown to be associated with
faster progression19 and the cohort in Southern Europe
was younger, thus in an earlier stage of disease progression
in each calendar period.
RESULTS
Characteristics of the study population are shown in
table 1. During the study period 166 persons developed
AIDS and 200 persons died,
of whom 88 did so prior to
the development of AIDS.
Since the application of the
extended AIDS case defini-
tion, 101 individuals had
developed AIDS, 20% as a
result of one of the added
diseases (17 pulmonary TB
and three recurrent pneumo-
nia). Following the change
in AIDS case definition and
before HAART was intro-
duced, the risk of AIDS in-
creased by 29% (adjusted
hazard ratio 1.29 (1/0.77)
(table 2a), 95% confidence
interval (CI): 0.88–1.90).
Later on, after HAART
became available, the risk of
AIDS declined by 28% (adjusted HR for AIDS 0.72, 95%
CI: 0.41–1.25) (table 2a), using as reference the time
period during which the new AIDS case definition was
applied and before the introduction of HAART. When
ignoring the impact of the 1993 AIDS definition, thus
comparing only two calendar periods at risk (before and
after HAART), the impact of availability of HAART is
slightly less pronounced (adjusted HR 0.78 CI: 0.45–1.34,
not shown in the table). The reduction in risk of death
from natural causes after HAART compared to the total
period before is 36% (adjusted HR 0.64 (CI: 0.36–1.17)
(table 2b).
DISCUSSION
Until 1993 the incubation period from HIV sero-
conversion to AIDS in IDU was estimated to be 10.2–11.6
years.19–21 We assume the increased risk of AIDS in the
1993 to 1996 time period to be attributable to the
extension of the European AIDS case definition as two of
three added diseases are mainly afflicting IDU and no
changes in progression have been reported for earlier
calendar periods despite earlier definition changes and
the introduction of mono and bitherapy.22 However,
when ignoring this increased risk of AIDS that is probably
due to the 1993 AIDS definition, our estimated risk
reduction of AIDS among IDU in the time of highly
active antiretroviral therapy was altered only minimally.
Table 1 Characteristics of the study population (751 IDU
seroconverters)
Female 33%
Median age at HIV seroconversion 26 IQRa 22–30
<2 years between negative and 
positive HIV test 70%
Median seroconversion year 1990 IQR 1986–1992
Median years of follow-up 5.1 IQR 3.0–8.4
a: IQR: inter-quartile range
Table 2a Hazard ratios for progression from HIV seroconversion to AIDS by calendar period
AIDS
univariate
AIDS
multivariatea
Calendar period
Application of 1987 AIDS definition 0.65 (0.45–0.93) 0.77 (0.52–1.14)
1993 AIDS definition until HAART (reference) 1 1
Since availability of HAART 0.78 (0.45–1.35) 0.72 (0.41–1.25)
a: Adjusted for age at seroconversion, gender, geographic region and setting of follow up (hospital vs. non-hospital based).
Table 2b Hazard ratios for progression from HIV seroconversion to death of natural causes by calendar
period
Death
univariate
Death
multivariatea
Calendar period
Pre HAART 1 1
General availability of HAART 0.71 (0.39–1.27) 0.64 (0.36–1.17)
a: Adjusted for age at seroconversion, gender, geographic region and setting of follow up (hospital vs. non-hospital based).
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In our study, the first effect of the availability of HAART
among IDU with documented HIV seroconversion is an
approximate 28% decrease in risk of developing AIDS
and 36% decrease in mortality. The survival benefit in
our study is less than that reported in the CASCADE
study in the same study period, where the overall decrease
in mortality following HAART introduction was 64%,
with no difference by risk group.7 The survival benefit in
our study is also less than the 50% decrease in mortality
among Italian seroconverters. The latter study does
mention that the reduction was less pronounced among
IDU, but not to which extent.5 Not only less HAART
uptake, but also pre-AIDS deaths of natural causes (liver
failure, bacterial infections), which are more common
among IDU than other risk groups, may play a role in the
limited effect of HAART on mortality.12 Future analyses
including more follow-up time and details on individual
treatment compliance will let us know whether IDU do
indeed benefit less from the availability of HAART than
other risk groups.
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